<DOC>
	<DOCNO>NCT03093259</DOCNO>
	<brief_summary>This Phase IIa study 8-week , double-blind , placebo-controlled , randomize study aim evaluate safety efficacy ABX464 give day ( o.d ) 150 mg subject moderate severe Active Ulcerative Colitis fail intolerant immunomodulators , Anti-TNFα , vedolizumab and/or corticosteroid follow one-month follow-up period .</brief_summary>
	<brief_title>ABX464 Subjects With Moderate Severe Active Ulcerative Colitis</brief_title>
	<detailed_description>This Phase IIa study 8-week , double-blind , placebo-controlled , randomize study aim evaluate safety efficacy ABX464 give day ( o.d ) 150 mg subject moderate severe Active Ulcerative Colitis fail intolerant immunomodulators , Anti-TNFα , vedolizumab and/or corticosteroid follow one-month follow-up period . Eligible subject randomize accord 2/1 ratio two different group treatment . Randomized subject receive 150 mg ABX464 orally daily 56 day . At day 56 , ABX464 treatment stop subject follow one-month accord standard care</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Diagnosis moderate severe active UC confirm endoscopy histology least 12 week prior screen visit . Moderate severe active UC define Mayo Clinic Score ( MCS ) 6 12 inclusive ( scale 012 ) . Moderate severe active UC confirm screen visit centrally read MCS endoscopy score least 2 ( scale 03 ) ; Subjects receive oral corticosteroid must stable dose prednisone prednisone equivalent ≤20 mg/day ) beclomethasone diproprionate ( ≤5mg/day ) budesonide MMX ( ≤9mg/day ) , ≥2 week first dose ( i.e . baseline ) ; Topical corticosteroid topical 5aminosalicylic acid preparation must withdraw ≥2 week first dose ( i.e . baseline ) ; Subjects oral 5aminosalicylic acid must stable dose ≥4 week first dose ( i.e . baseline ) ; Subjects receive immunosuppressant form azathioprine , 6mercaptopurine , methotrexate need stable dose 4 week first dose ( i.e . baseline ) . Subjects take methotrexate also advise take folic acid 1 mg/day ( equivalent ) supplementation contraindication ; Subjects probiotic ( e.g. , Culturelle® [ Lactobacillus GG , iHealth , Inc. ] , Saccharomyces boulardii ) must stable dos 2 week first dose ( i.e . baseline ) ; Subjects antidiarrheal ( e.g. , loperamide , diphenoxylate atropine ) must stable dos 2 week first dose ( i.e . baseline ) ; Subjects previously receive antitumor necrosis factor ( TNF ) therapy vedolizumab must discontinue therapy ≥8 week first dose ( i.e . baseline ) ; Subjects previously treat cyclosporine tacrolimus must discontinue therapy ≥4 week first dose ( i.e . baseline ) ; Subjects previously treat tube feeding , define formula diet , parenteral alimentation/nutrition must discontinue treatment 3 week first dose ( i.e . baseline ) . Subject Crohn 's Disease ( CD ) , indeterminate colitis ( IC ) presence history fistula CD ; History toxic megacolon , abdominal abscess , symptomatic colonic stricture stoma ; history imminent risk colectomy ; History current evidence colonic dysplasia adenomatous colonic polyp . Subject severe gastrointestinal complication ; e.g. , short bowel syndrome , obstruct stricture , recent plan bowel surgery , Ileostomy and/or colostomy , recent bowel perforation ; Subject significant know active infection screen Infected abscess , positive Clostridium difficile ( stool antigen toxin ) , CMV , TB recent infectious hospitalization ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ABX464</keyword>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>Refractory</keyword>
</DOC>